LEIGHA WACHS: Open Payments
NPI 1558024307 · CINCINNATI, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$510 in 35 payments from 11 companies in 2025. Trend: 2023 $584 · 2024 $996 · 2025 $510
Food & beverage: $510
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $189 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Alkermes, Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
| Neos Therapeutics, LP | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $15 |
Products named: VRAYLAR, TRINTELLIX, REXULTI, Qelbree, ARISTADA, ABILIFY MAINTENA, HETLIOZ, CAPLYTA.
Industry payments across OH — which companies pay providers there.
